Clinical Trials

Melanoma

NCT02196181 2026-03-18

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

280 enrolled

Melanoma

NCT03190915 2026-03-18

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

CNSOther hematologic neoplasm

10 enrolled 11 charts

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03919071 2026-03-18

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

58 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma

NCT04439292 2026-03-18

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Phase 1/2 Active not recruiting

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04557956 2026-03-18

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

Melanoma

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 3 Active not recruiting

60 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT04439279 2025-11-19

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled 10 charts

Phase 1 Active not recruiting

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02015117 2025-10-23

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

10 enrolled

CNS

Brain Neoplasms

NCT02079740 2025-09-30

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

96 enrolled 30 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Phase 1 Completed

46 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Completed

27 enrolled 16 charts

DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT03148275 2024-11-26

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

44 enrolled 12 charts

Hemangioendothelioma, Epithelioid

NCT02097225 2024-10-16

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

22 enrolled 21 charts

Melanoma, Neoplasm Metastasis

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04566133 2023-08-21

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Phase 2 Terminated

2 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

15 enrolled

Melanoma

NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 1 Completed

26 enrolled

Gynecologic

Endometrial Adenocarcinoma

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Other hematologic neoplasm

37 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01907815 2018-04-06

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Phase 2 Terminated

24 enrolled 6 charts

Leukemia, Myeloid, Acute

NCT02042443 2017-09-12

S1310